💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, priced for perfection.
Aurobindo Pharma is scored on the pharma / healthcare framework. It keeps a healthy 10.3% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.58× reported profit. Free cash flow is worth about 2.0% of its market value.
Over the last 3 years revenue compounded at 11%/yr and profit at 22%/yr. Book value has grown 12%/yr. Return on equity is a modest 10.1%. In the latest quarter profit grew 12% versus the prior quarter.
At 30× earnings, the stock sits at the 89th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price implies ~13%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 25.93 | — | — |
| P/B | 2.62 | 4.11 | better |
| EV/EBITDA | 12.38 | 19.15 | better |
| ROE | 10.13 | — | — |
| ROCE | 12.76 | 6.87 | better |
| ROA | 6.46 | 1.26 | better |
| Quick Ratio | 1.15 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 11% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (22% vs 11%) — margin expansion is at work.
Operating margin has expanded from 10% to 15% — the business is keeping more of each rupee earned.
ROE at 9% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 22% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.6× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating.
Profit jumped 12% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 51.9% — majority control intact. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction. MF stake down 3.2pp — domestic funds are booking profits or rebalancing out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.